Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 4185 results
Stanford, SRI to support development of novel drugs to treat triple-negative breast cancer
A new collaborative project between scientists at SRI International and physician-researchers from Stanford Cancer Institute will support development of novel drugs for treatment of triple-negative breast cancer.
Drug Research > Drug Discovery & Development > News
Pfizer joins human vaccines project to help decode immune system
Pfizer will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection.
Drug Research > Drug Discovery & Development > News
Harvard University collaborates with Merck to develop novel cancer therapeutics
Harvard University has entered into an exclusive license and research collaboration agreement with Merck, known as MSD outside the United States and Canada, to further the development of small-molecule therapeutics for leukemia and other cancers.
Drug Research > Drug Discovery & Development > News
University of Manchester scientists to develop Zika virus vaccine
By PBR Staff Writer
Scientists at the University of Manchester are developing a new vaccine against the mosquito-borne Zika virus.
Drug Research > Drug Discovery & Development > News
Omnis Pharma, Magnis merge to form clinical-stage oncolytic immunovirotherapy development firm
By PBR Staff Writer
Omnis Pharma and Magnis Therapeutics have merged to establish Vyriad, a clinical-stage oncolytic immunovirotherapy development company.
Drug Research > Drug Discovery & Development > News
FDA committee to review Sarepta's NDA for eteplirsen to treat duchenne muscular dystrophy
Sarepta Therapeutics announced that the Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee of the US Food and Drug Administration (FDA) will review Sarepta’s New Drug Application (NDA) for eteplirsen on April 25, 2016.
Drug Research > Drug Discovery & Development > News
Wistar Institute and PhoreMost launch drug discovery collaboration
The Wistar Institute and PhoreMost have announced the formalization of a multi-project research partnership that combines Wistar’s knowledge and propriety biological systems with PhoreMost’s drug discovery expertise and unique screening capabilities.
Drug Research > Drug Discovery & Development > News
Aspyrian Therapeutics secures $40m series B financing
Aspyrian Therapeutics, a clinical stage drug development company creating precision-targeted therapies to treat cancer based on its Photoimmunotherapy platform, has secured $40m as part of a Series B financing.
Drug Research > Drug Discovery & Development > News
Cancer firm Aprea closes EUR46m Series B financing
Aprea AB, a clinical-stage biotechnology company developing novel anticancer therapies targeting the tumor suppressor protein p53, has completed a Series B financing round, raising EUR46m (approximately $51m).
Drug Research > Drug Discovery & Development > News
Tizona Therapeutics completes $43m Series B financing
Tizona Therapeutics, a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases, announced the closing of a $43m Series B financing.
Drug Research > Drug Discovery & Development > News
BioCryst's BCX4430 drug improves survival rates in mice infected with Zika virus
By PBR Staff Writer
BioCryst Pharmaceuticals said a dose of its experimental antiviral drug, BCX4430, improved survival rates in mice infected with the Zika virus in a preclinical study.
Drug Research > Drug Discovery & Development > News
Royalty Pharma acquires rights to UCLA's Xtandi cancer drug for $1.14bn
By PBR Staff Writer
Royalty Pharma has acquired University of California, Los Angeles' (UCLA) royalty interest in the prostate cancer drug Xtandi (enzalutamide) for $1.14bn.
Drug Research > Drug Discovery & Development > News
Ensemble Therapeutics achieves early-stage research milestone in drug discovery collaboration with Alexion
Ensemble Therapeutics has achieved an early-stage research milestone in its drug discovery collaboration with Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), triggering a milestone payment to Ensemble.
Drug Research > Drug Discovery & Development > News
Two UK biotechnology companies form immuno-oncology joint venture
By PBR Staff Writer
Two UK biotechnology companies Horizon Discovery Group and Centauri Therapeutics have formed an immuno-oncology joint venture (JV) to focus on developing cancer treatments.
Drug Research > Drug Discovery & Development > News
Two Texas hospitals develop rapid tests for Zika virus
By PBR Staff Writer
Two Texas medical centers have developed what they are claiming the country's first hospital-based rapid tests for the Zika virus.
Drug Research > Drug Discovery & Development > News
61-75 of 4185 results